Plasma cell myeloma refractory

9 trials 7 recruiting MedDRA PT
9 Registered trials
7 Recruiting
3 Unique sponsors
9 Unique IMPs
9 Commercial trials
Drug classes (ATC)
— ATC code not specified 5
H Endocrinology (ATC H) 4
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Monoclonal antibody (rat) 1 substance
Corticosteroid 1 substance
Monoclonal antibody (chimeric) 1 substance
IMiD 1 substance
Antibody-drug conjugate (ADC) 1 substance
Receptor fusion protein 1 substance
Phase III: 1 Phase II: 1 Phase I/II: 5 Phase I: 2

Filter these 9 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 9 trials

Phase III

1 trial
  • Janssen - Cilag International Commercial
    IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D; TECLISTAMAB
    2025-522007-18-00 7 countries 2026 n=157 Orphan
    Recruiting

Phase II

1 trial
  • Janssen - Cilag International Commercial
    IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
    2025-521976-80-00 2 countries 2026 n=54
    Recruiting

Phase I/II

5 trials
  • Sanofi-Aventis Recherche & Developpement Commercial
    DEXAMETHASONE; ISATUXIMAB; POMALIDOMIDE
    2024-514988-25-00 6 countries 2021 n=7
    Recruiting
  • Sanofi-Aventis Recherche & Developpement Commercial
    BELANTAMAB MAFODOTIN; DEXAMETHASONE; ISATUXIMAB
    2024-514989-40-00 3 countries 2021 n=3 Orphan
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    ISATUXIMAB; PEGENZILEUKIN
    2024-514990-23-00 6 countries 2021 n=27
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    BELUMOSUDIL MESILATE; DEXAMETHASONE; ISATUXIMAB
    2024-514992-16-00 6 countries 2021 n=17 Orphan
    Recruiting
  • Sanofi-Aventis Recherche & Developpement Commercial
    DEXAMETHASONE; EVORPACEPT; ISATUXIMAB
    2024-514993-38-00 6 countries 2021 n=19 Orphan
    Recruiting

Phase I

2 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IMP not specified
    2023-506993-11-00 1 country 2023 n=22
    Recruiting
  • Sanofi-Aventis Recherche & Developpement Commercial
    IMP not specified
    2024-511667-28-00 3 countries 2025 n=29
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Sanofi-Aventis Recherche & Developpement Commercial 6 Phase I, Phase I/II 4
Janssen - Cilag International Commercial 2 Phase II, Phase III 2
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase I 1
New trials by year
2021
5
2023
1
2025
1
2026
2
← All indication landscapes